CDC/ACIP [to 15 July 2017]

CDC/ACIP [to 15 July 2017]
http://www.cdc.gov/media/index.html

MMWR News Synopsis for July 13, 2017

Measles Outbreak — Minnesota, April–May 2017
Recent U.S. and international measles cases are concerning and serve as a reminder of the seriousness of the disease and the importance of vaccination. Addressing parents’ questions and concerns and correcting misinformation about childhood vaccines through healthcare professionals and other trusted community leaders is critical in protecting children and communities from vaccine-preventable diseases. Since April 2017, a measles outbreak in Minnesota has been demonstrating the importance of maintaining high vaccination rates to protect communities from measles. Measles quickly spread in an under-vaccinated population, resulting in a large-scale and intensive public health response to prevent further illnesses and possible deaths. The outbreak also highlighted the importance of building trust with communities and identifying effective, culturally appropriate ways to address questions, concerns, and misinformation about the MMR vaccine.

Pneumococcal Vaccination Among Medicare Beneficiaries Following the Advisory Committee on Immunization Practices Recommendation for Routine Use of 13-valent Pneumococcal Conjugate Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years
Providers should ensure that older adults initiate and complete the recommended pneumococcal vaccination series to reduce their risk of contracting pneumococcal disease. To reduce the burden of pneumococcal disease, providers should ensure that older adults initiate and complete the recommended pneumococcal vaccination series. CDC analyzed claims for vaccination submitted for reimbursement to the Centers for Medicare & Medicaid Services (CMS) to help measure PCV13 and PPSV23 vaccination uptake among adults aged ≥65 years before and after implementation of revised recommendations in September 2014. By September 18, 2016, 43.2 percent of Medicare Parts A and B beneficiaries aged ≥65 years had claims for at least one dose of PPSV23 (regardless of PCV13 status), 31.5 percent had claims for at least one dose of PCV13 (regardless of PPSV23 status), and 18.3 percent had claims for at least one dose each of PCV13 and PPSV23.